Fused furans for the treatment of hepatitis C

Patent metadata

Field	Value
Publication number	US-9738653-B2
Application number	US-201414773123-A
Country	US
Kind code	B2
Filing date	Mar 12, 2014
Priority date	Mar 14, 2013
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

The disclosure provides compounds of formula I or II, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

First claim

We claim:

1. A compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

2. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. A method of treating hepatitis C infection comprising administering a therapeutically effective amount of a compound of claim 1 to a patient.

Assignees

• Bristol Myers Squibb Co

Inventors

• Yeung Kap-Sun
• Eastman Kyle J
• Parcella Kyle E

Classifications

• C07D491/048 Primary

  the oxygen-containing ring being five-membered · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07D491/04

  Ortho-condensed systems · CPC title

• C07D307/84

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title